Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3

Wells Fargo analyst Evan Stampler maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5.5 to $3.